Cambium Bio Limited has released a press release.
Re-Released - Appendix 4C - Quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Cambium Bio
- Progenza patent to grant in Europe
- Regeneus receives R&D tax incentive refund of $2.4m
- Positive clinical trial results for cancer vaccine
- US Patent Office to allow key patent for Progenza
- Update on licensing Progenza in Japan
Later from Cambium Bio
- Chinese patent granted for biomarkers for stem cell therapy
- New CEO Appointed to Accelerate Global Growth
- Response to ASX Appendix 4C Query Letter
- Directors Provide $2.5M Loan to Extend Funding Runway
- Positive results for Progenza in treating neuropathic pain
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio